SkyCell funding news – Pharmatech Company SkyCell Secures $116Million in Series D Round Funding

To further support their pharma customers’ Scope 3 decarbonization efforts, they are significantly increasing their fleet size to offer additional solutions that further reduce CO2 emissions beyond the 50% reduction already achieved by their containers compared to the competition.

The series D funding includes $59 million from the Asia-based global growth investor Tybourne Capital Management, and CC Industries (CCI), the Chicago-based holding company for the Crown family. This follows a $57 million equity investment from Catalyst, M&G Investments’ purpose-led private assets strategy.

They are proud to welcome their new partners/investors and look forward to their continued partnership. Tybourne Capital Management is a global, growth-oriented, fundamental equity investor in public and private markets. The Hong Kong-headquartered firm, founded in 2012, manages long-duration capital on behalf of prominent non-profits, university endowments, sovereigns, corporate pensions and family offices.

Read also - CellPoint Digital partnership news – London-based CellPoint Digital Announced New Partnership with Nexus Tours

CCI, an affiliate of Henry Crown and Company, is a Chicago-based holding company for the Crown family. CCI invests, via late-stage venture and growth equity, in businesses focused on environmental sustainability. The family enterprise was founded in 1919 by Henry Crown and his brothers.

This substantial investment will enable them to further enhance their innovative solutions and solidify their position as a key player in the pharmaceutical logistics sector.

Bosun Hau, Managing Director At Tybourne Capital Management “I am delighted to join SkyCell’s board at this significant moment in the Company’s growth. With its lead in hardware as well as software and tracking platform offering SkyCell is well positioned to become the technology partner of choice to the global pharmaceutical industry well beyond its current cold-chain logistics business. Global supply chains are becoming increasingly complex, and managing risk is a board-level issue for nearly every sector – for pharmaceutical companies in particular, it is mission-critical. SkyCell has developed a comprehensive state-of-the-art system combining hardware, software, and big data that is transforming pharmaceutical logistics. "

Dr. Remo Gerber, Cfo, Skycell said, “Gaining CCI and Tybourne as investors significantly broadens our footprint in the US and Asia and is a testament to our high growth based on strong financial business fundamentals. Having built the technological foundations in cold chain hardware and software/IoT-enabled tracking, this investment enables us to commercialize our platform into adjacent pharma market segments, significantly expanding our total addressable market beyond cold chain packaging.”

Richard Ettl, Co-Founder and CEO of Skycell said, “Our reusable 1500X container saves, on average, 50% CO2 or, in absolute terms, 8 tons CO2e per use. This means for a typical pharma customer today we save more than 250,000 tons of CO2 every year without compromising quality. And finally, digitalization is coming to pharma supply chains – moving away from manual worksheets to integrated workflows that leverage S+O data (simulated and operational data) from our proprietary pool of billions of data points. Combined with the power of AI, this enables significant reductions in both cost and risk for our customers. With this new investment, we can further optimize supply chains and create truly sustainable logistics.”

About SkyCell

SkyCell, the pioneering Swiss company revolutionizing global pharmaceutical logistics by providing cutting-edge temperature-controlled hybrid containers.

Powered by data-driven technology, SkyMind the supply chain operating system, optimizes the pharmaceutical supply chain by reducing and predicting the risk of damaging valuable cargo. With an industry-leading temperature excursion rate of less than 0.05% and a profound reduction in CO2 emissions, our innovative approach has been validated by leading pharma companies and trusted by major airlines.